What's Happening?
Pulse Biosciences, Inc., a company specializing in Nanosecond Pulsed Field Ablation technology, has released its financial results for the second quarter of 2025. The company reported a GAAP net loss of $19.2 million, an increase from $11.4 million in the same period last year. Non-GAAP net loss was $13.7 million, up from $9.0 million in 2024. The rise in expenses is attributed to administrative costs related to clinical trials and commercialization efforts. Pulse Biosciences is advancing its nsPFA technology across several medical applications, including soft tissue ablation and atrial fibrillation treatment. The company has expanded its pilot program for soft tissue ablation and submitted FDA IDE applications for cardiac surgical and catheter systems.
AD
Why It's Important?
The financial results and business updates from Pulse Biosciences highlight the company's ongoing investment in innovative medical technologies. The increased expenses reflect the company's commitment to advancing its nsPFA technology, which has the potential to transform treatment options for conditions like atrial fibrillation and benign thyroid disease. The successful development and commercialization of these technologies could significantly impact the healthcare industry by providing new, non-invasive treatment options. Investors and stakeholders are closely monitoring the company's progress, as its technology could lead to improved patient outcomes and potentially reduce healthcare costs.
What's Next?
Pulse Biosciences plans to commence enrollment in a post-market study for benign thyroid disease treatment in the third quarter of 2025, pending IRB approvals. The company is also preparing to start IDE pivotal studies for its cardiac surgical and catheter systems. These steps are crucial for obtaining premarket approval and expanding the clinical use of its nsPFA technology. The outcomes of these studies will be pivotal in determining the future commercial success of Pulse Biosciences' products.
